
via University of Manchester
Scientists have discovered a new route to produce complex antibiotics exploiting gene editing to re-programme pathways to future medicines urgently required to combat antimicrobial resistance, treat neglected diseases and tackle future pandemics.
Researchers from The University of Manchester have discovered a new way of manipulating key assembly line enzymes in bacteria which could pave the way for a new generation of antibiotic treatments.
New research published today in Nature Communications, describes how CRISPR-Cas9 gene editing can be used to create new nonribosomal peptide synthetase (NRPS) enzymes that deliver clinically important antibiotics. NRPS enzymes are prolific producers of natural antibiotics such as penicillin. However, up until now, manipulating these complex enzymes to produce new and more effective antibiotics has been a major challenge.
The UK government suggest antimicrobial resistance (AMR) infections are estimated to cause 700,000 deaths each year globally and are predicted to rise to 10 million, costing the global economy $100 trillion, by 2050. AMR also threatens many of the UN’s Sustainable Development Goals (SDGs), with an extra 28 million people that could be forced into extreme poverty by 2050 unless AMR is contained.
The Manchester team says the gene editing process could be used to produce improved antibiotics and possibly lead to the development of new treatments helping in the fight against drug-resistant pathogens and illnesses in the future. Jason Micklefield, Professor of Chemical Biology at the Manchester Institute of Biotechnology (MIB), UK, explains: “The emergence of antibiotic-resistant pathogens is one of the biggest threats we face today.”
“The gene editing approach we developed is a very efficient and rapid way to engineer complex assembly line enzymes that can produce new antibiotic structures with potentially improved properties.”
The emergence of antibiotic-resistant pathogens is one of the biggest threats we face today. The gene editing approach we developed is a very efficient and rapid way to engineer complex assembly line enzymes that can produce new antibiotic structures with potentially improved properties.
Professor Jason Micklefield
Microorganisms in our environment, such as soil dwelling bacteria, have evolved nonribosomal peptide synthetase enzymes (NRPS) that assemble building blocks called amino acids into peptide products which often have very potent antibiotic activity. Many of the most therapeutically important antibiotics, used in the clinic today, are derived from these NRPS enzymes (e.g. penicillin, vancomycin and daptomycin).
Unfortunately, deadly pathogens are emerging which are resistant to all of these existing antibiotic drugs. One solution could be to create new antibiotics with improved properties that can evade the resistance mechanisms of the pathogens. However, the nonribosomal peptide antibiotics are very complex structures which are difficult and expensive to produce by normal chemical methods. To address this, the Manchester team use gene editing to engineer the NRPS enzymes, swapping domains that recognise different amino acid building blocks, leading to new assembly lines that can deliver new peptide products.
Micklefield added: “We are now able to use gene editing to introduce targeted changes to complex NRPS enzymes, enabling alternative amino acids precursors to be incorporated into the peptide structures. We are optimistic that our new approach could lead to new ways of making improved antibiotics which are urgently needed to combat emerging drug-resistant pathogens.”
Original Article: Manchester scientists produce new antibiotics by gene editing
More from: University of Manchester
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
New antibiotics development
- Air pollution renders antibiotics ineffective
A ‘Lancet’ study has established a connection between bacterial antibiotic resistance and air pollution; inhaling PM 2.5 can lead to antibiotic resistance There was a sense of palpable urgency to ...
- Natural antibiotic thiostrepton reveals new hope for inflammatory bowel disease treatment
Researchers explored the therapeutic impact of Thiostrepton on experimental colitis by examining its effects on colon inflammation and determining its targets through various biochemical approaches.
- Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia
Using a pre-defined non-inferiority margin of 15%, treatment with ceftobiprole was non-inferior to daptomycin with overall treatment success achieved in 69.8% of patients in the ceftobiprole group ...
- Lethal weapon: New antimicrobial coating could revolutionize cleaning methods
We've gained a new weapon in the fight against harmful and often antibiotic-resistant pathogens with the development of a unique material engineered to limit disease spread and replace current ...
- Stemming the tide of antibiotic resistance – researchers shed light on the complexities of hospital wastewater treatment
In a paper published in the Journal of Chemical Technology and Biotechnology, a multidisciplinary team including biologists, chemists, chemical engineers, and environmental scientists have ...
Go deeper with Google Headlines on:
New antibiotics development
[google_news title=”” keyword=”new antibiotics development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibiotic treatments
- New antibiotic ceftobiprole shows promise against resistant staph infections
New research shows that an antibiotic effective for bacterial pneumonia also appears to fight treatment-resistant staph infections.
- What's behind the amoxicillin shortage expected by the FDA and tips to find the antibiotic in Milwaukee
According to the FDA's drug shortage database, the shortage affects amoxicillin powder, which is mixed to make the liquid formulation of the drug. The liquid drug is often used to treat children, and ...
- Antibiotic shows effectiveness against deadly staph infections
An antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health.
- Natural antibiotic thiostrepton reveals new hope for inflammatory bowel disease treatment
Researchers explored the therapeutic impact of Thiostrepton on experimental colitis by examining its effects on colon inflammation and determining its targets through various biochemical approaches.
- Dear Doctor: Are antibiotics necessary prior to dental procedures for people with prosthetic joints?
ANSWER: The guidelines weren’t as clear, but they are now. Antibiotics do not need to be given prior to a dental procedure in people with prosthetic joints, like a knee or a hip, even in the first few ...
Go deeper with Google Headlines on:
Antibiotic treatments
[google_news title=”” keyword=”antibiotic treatments” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]